Notably, a recent meta-analysis by Bhalraam et al. reported a stronger cardioprotective effect of SGLT2 inhibitors in breast cancer patients treated with anthracyclines compared to those undergoing other treatments [76]. This evidence concerns the gene SLC5A2 and breast cancer.